Observational studyPloS one2026
The effects of stimulated thyroglobulin/ thyroid-stimulating hormone ratio and N1b status on the efficacy of the first I-131 treatment in patients with differentiated thyroid cancer.
Observational study in PloS one, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThyroglobulin (Tg) level is one of the well-known factors affecting the outcome of radioactive iodine treatment in differentiated thyroid cancer, though this tumor marker is affected by the thyroid-stimulating hormone (TSH) level. To negate this influence, there is an effort to use the stimulated thyroglobulin/ thyroid-stimulating hormone (sTg/TSH) ratio instead of stimulated thyroglobulin (sTg) level alone. N1b cervical lymph node metastasis is also another factor mentioned in literature. This study aims to demonstrate the significance of these two factors whether they affect the treatment outcome in differentiated thyroid cancer patients who received the first radioactive iodine treatment.
methodsThis was a retrospective analytical observational study. The population were patients with differentiated thyroid cancer with an age of 18 years and above who received the first radioactive iodine treatment at our center from 1 January 2020-31 December 2023. The total population was 227 patients. Logistic regression analysis was done to determine the significant factors affecting the outcome of the first radioactive iodine treatment.
resultsIn 227 patients, the median value for sTg and sTg/TSH ratio were 9.4 ng/mL and 0.2, respectively. Multiple logistic regression found that sTg/TSH ratio and N1b status were not independent risk factors for non-excellent response after radioactive iodine treatment. The independent risk factors were male sex, intermediate and high risk of recurrence, stage II and sTg of more than or equal to 9.4 ng/mL. Receiver operating characteristic (ROC) analysis showed that sTg and sTg/TSH ratio had rather similar performance in differentiating between excellent and non-excellent response groups.
conclusionsTg/TSH ratio and N1b cervical lymph node metastasis were not significant independent factors for non-excellent response after the first radioactive iodine treatment, which was possibly due to multicollinearity and small sample size. Independent risk factors for non-excellent response of the first radioiodine treatment were male sex, intermediate and high risk of recurrence, stage II and sTg of more than or equal to 9.4 ng/mL.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.